XML 31 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Payments (Tables)
9 Months Ended
Jan. 31, 2021
Share-based Payment Arrangement [Abstract]  
Summary of allocation of share based compensation expense
Stock-based compensation expense was recognized as follows (table in thousands):
 
Three Months Ended
January 31,
Nine Months Ended
January 31,
 2021202020212020
General and administrative$149 $110 $206 $281 
Sales and marketing51 95 148 144 
Research and development16 
Cost of oncology services25 20 67 
Total stock-based compensation expense$232 $229 $437 $437 
Summary of valuation assumptions for stock options
Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2021 and 2020 were as follows:
 
Three Months Ended
January 31,
Nine Months Ended
January 31,
 2021202020212020
Expected term in years
3
3-6
3-6
3-6
Risk-free interest rates
0.12%
1.57%-1.80%
0.12%-0.39%
1.57%-1.80%
Volatility
74.98%
69.14%-70.99%
72.64%-74.98%
69.14%-71.11%
Dividend yield—%—%—%—%
Summary of stock option activity
The Company’s stock options activity for the nine months ended January 31, 2021 was as follows:
 
Directors
and
Employees
Non-
Employees
TotalWeighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
Outstanding, April 30, 20202,228,326 43,332 2,271,658 $3.23 5.0$10,663,000 
Granted133,833 — 133,833 9.21 7.58
Exercised(662,285)(1,159)(663,444)2.27 
Forfeited(7,000)— (7,000)6.43   
Canceled(34,978)(923)(35,901)4.03 
Expired— (5,834)(5,834)10.80   
Outstanding, January 31, 20211,657,896 35,416 1,693,312 4.02 5.66$11,975,000 
Vested and expected to vest as of January 31, 20211,657,896 35,416 1,693,312 4.02 5.66$11,975,000 
Exercisable as of January 31, 20211,289,104 9,584 1,298,688 3.25 4.93$10,173,000